| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.057 | 0.2 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.2 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |